
VIP (10mg)
Spécifications techniques
| Pureté (HPLC) | ≥95% (HPLC) |
| Numéro CAS | 37221-79-7 |
| Forme | White lyophilized powder |
| Stockage | -20°C |
| Séquence | His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH₂ |
| Poids moléculaire | 3,326.82 g/mol |
| Forme saline | Acetate |
| Solubilité | Soluble in water |
VIP (10mg)
Prix catalogue EUR · HU, SK, CZ, PL
- Eurozone (EUR)144,00 EUR
- Hongrie (HU)144,00 EUR≈ 57 600 Ft
- Slovaquie (SK)144,00 EUR
- Tchéquie (CZ)144,00 EUR≈ 3 600 Kč
- Pologne (PL)144,00 EUR≈ 612,00 zł
Même prix catalogue en EUR pour livraison vers la Hongrie, la Slovaquie, la République tchèque et la Pologne. Paiement en EUR.
Montants HUF/CZK/PLN indicatifs convertis depuis l’EUR ; la Slovaquie utilise l’EUR. Taux approximatifs. Paiement en EUR.
Vasoactive Intestinal Peptide — 28-amino-acid neuropeptide for inflammation and vascular research. 10mg vial.
Strictement réservé à la recherche en laboratoire.
Non destiné à la consommation humaine, vétérinaire ou au diagnostic.
From the Peptide Explorer
A 28-amino-acid neuropeptide found throughout the central and peripheral nervous systems, GI tract, and immune cells. VIP acts on VPAC1 and VPAC2 receptors to mediate vasodilation, smooth muscle relaxation, immune regulation, and neuroprotection across multiple organ systems.
Key Mechanisms
- ›VPAC1/VPAC2 receptor agonism
- ›Vasodilation via cAMP
- ›Anti-inflammatory cytokine regulation
- ›Neuroprotective signaling
- ›Smooth muscle relaxation
Primary Research Areas
- ›Neuroprotection
- ›Autoimmune disease
- ›Lung protection
- ›GI motility
- ›Vasodilation
Key Research Findings
- Demonstrated neuroprotective effects in Parkinson's and Alzheimer's models
- Aviptadil (synthetic VIP) advanced to clinical trials for ARDS
- Potent anti-inflammatory effects in autoimmune disease models
Research Overview
A 28-amino-acid neuropeptide found throughout the central and peripheral nervous systems, GI tract, and immune cells. VIP acts on VPAC1 and VPAC2 receptors to mediate vasodilation, smooth muscle relaxation, immune regulation, and neuroprotection across multiple organ systems.
Origin: Discovered in porcine intestinal extracts by Said & Mutt, 1970
Mechanism of Action
- VPAC1/VPAC2 receptor agonism
- Vasodilation via cAMP
- Anti-inflammatory cytokine regulation
- Neuroprotective signaling
- Smooth muscle relaxation
Primary Research Areas
- Neuroprotection
- Autoimmune disease
- Lung protection
- GI motility
- Vasodilation
Key Published Findings
- Demonstrated neuroprotective effects in Parkinson's and Alzheimer's models
- Aviptadil (synthetic VIP) advanced to clinical trials for ARDS
- Potent anti-inflammatory effects in autoimmune disease models
Research Protocol
Commonly studied routes: Intravenous, Subcutaneous, Intranasal. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized
Important Notice
VIP (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Spécifications de recherche
Synthesized for strict analytical consistency. Verified via HPLC/MS.Voir les standards qualité →
Manipulation et stockage
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water